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"My first thought was, what about the baby?" stated Tracy Hartman, a woman who is six 
weeks pregnant, after doctors told her that she had cervical cancer (University of California 
Davis Health System, 2010, p. 1). A diagnosis of cancer is devastating to a mother who is often 
overjoyed by the prospect of parenthood. Because the diagnosis of cancer during pregnancy is a 
relatively rare complication, 1 in 1,000 pregnancies, large-randomized-controlled trials are 
difficult to conduct. As a result, data is noticeably absent to support definitive treatment 
guidelines (Pavlidis, 2002; Pereg, Koren, & Lishner, 2008).  Although there are no definitive 
guidelines for treatment, researchers agree that management of the disease must be patient 
specific (Van Calsteren et al., 2010).  The purpose of this paper is to present current options for 
management of cancer during pregnancy and to discuss the ethical issues of beneficence, 
nonmaleficence and autonomy of the mother and fetus related to the treatment options. 
Review of the Literature 
According to the Center for Disease Control, there is a rise in the rate of births to women 
over the age of 35 (Mathews & Hamilton, 2009). From 1970 to 2006, the proportion of first 
births to women over the age of 35 increased nearly eight times.  In 2006, nearly 1 out of 12 first 
births were to women over the age of 35 (Mathews & Hamilton, 2009).  The incidence of cancer 
in the 30 to 49 years-old age group is increasing (Van Calsteren et al., 2010). With the rates of 
pregnancy and cancer rising in the same population, they will inevitably collide. There will be a 
higher rate of cancer diagnoses in pregnant women.  
The most common cancers in pregnancy are cervical, breast, and ovarian, followed by 
malignant melanoma, lymphoma, and leukemia (Moran, Yano, Al Zahir, & Farquharson, 2007).  
Cancer treatment during pregnancy is a challenge requiring the efforts of a multidisciplinary 
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team. There are two key concerns when considering treatment options: how the pregnancy 
affects the behavior of the cancer and how the cancer and its treatment affect the pregnancy 
(Moran et al., 2007). Therapeutic approaches to manage cancer during pregnancy include 
surgery, radiotherapy and chemotherapy.  
Moran et al. (2007) concluded that surgery during pregnancy has been shown to be 
relatively safe.  However, they recommend delaying non-emergent surgery until the second 
trimester.  Waiting until the second trimester reduces the risk of fetal harm, induction of abortion 
and premature labor. When surgery is not an option, treatment teams may then consider 
radiotherapy or chemotherapy. 
David Pereg et al. (2008) created a decision tree for the treatment of cancer during 
pregnancy.  If a mother is diagnosed in the first trimester and would like to pursue radiation or 
chemotherapy, it is suggested that the mother consider terminating the pregnancy.  During the 
first trimester, the fetus is undergoing organogenesis. Exposure to radiation or chemotherapy 
during organogenesis can result in congenital malformations, spontaneous abortions and even 
fetal death.  First trimester exposure to chemotherapy has been associated with 10-20% risk of 
major malformations (Weisz, Meirow, Schiff, & Lishner, 2004).   
In the second and third trimester, the mother may consider delaying treatment until 
achieving fetal maturity.  If treatment delay is possible, the mother will go untreated but will be 
followed closely by the medical team.  Often physicians will perform a cesarean section or 
induce labor at the end of the 34
th
 week of gestation, when fetal maturity is achieved.  One study 
showed that 71.7% (n=129) of pregnancies were induced or had elective cesarean section at a 
mean gestational age of 35.6 weeks (Van Calsteren, et al., 2010). If treatment delay is not 
possible, chemotherapy may be administered in both trimesters. If radiation is the proposed 
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treatment, it is recommended that the mother terminate her pregnancy if she is in the second 
trimester.  Radiation given 8-25 weeks after conception is associated with up to 40% risk for 
severe mental retardation (Otake & Schull, 1998). Radiation may be given in the third trimester 
after an estimation of fetal dose is calculated by a medical physicist (Pereg et al., 2008).   Each of 
the therapeutic treatment options carries its potential complications to the mother and/or to the 
fetus.  The potential maternal-fetal conflict raises complex ethical dilemmas. 
When a pregnant female is diagnosed with cancer, her decision to treat or not treat the 
cancer could cause her and the treatment team moral stress. A pregnant woman with cancer will 
have to make life or death decisions for herself and her unborn child and it is the responsibility of 
the interdisciplinary treatment team to unbiasedly guide her through the treatment options 
(Visco, Meyer, Xi, & Brown, 2009).   The mother is the major beneficiary from anti-cancer 
treatment; consequently, the fetus would be placed at a substantial risk for congenital 
malformations or death.  The decision to administer chemotherapy or radiation, or to terminate 
the pregnancy, is indicated with a poor maternal prognosis or when cytotoxic treatment is 
indicated in the first trimester (Van Calstern et al., 2010).  In one study, the main indication for 
terminating pregnancy in 29 of 30 mothers was maternal malignancy (Van Calstern et al., 2010).  
If the mother chooses this treatment option, the treatment team would be practicing the ethical 
principle of beneficence—promote good—when looking at the treatment of the mother; 
however, they are violating the principle of nonmaleficence—do no harm—in relation to the 
fetus.  
The second option is to delay treatment to allow the fetus to grow, develop and become 
viable.  By postponing medical interventions, the fetus’s well-being is preserved.  Delaying 
treatment may be harmful to the mother as it allows time for her cancer to grow and possibly 
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metastasize. Nettleton et al. (1996) presented a mathematical model to quantify the risk of 
axillary nodal metastasis as a result of delayed treatment in breast cancer during pregnancy.  
They calculated that there is a daily increased risk of 0.028% for tumors with moderate doubling 
times of 130 days and 0.057% for tumors with rapid doubling times of 65 days.  If this option is 
chosen, then beneficence is shown to the fetus and nonmaleficence is breached with regard to the 
mother. 
The decision to treat or not treat cancer during pregnancy includes great legal and ethical 
fetal rights debates (Harris, 2000).  Some bioethical models assert that the health care team has 
an ethical obligation to the fetus as a patient, because the health care team can care for it 
medically (Harris, 2000; Harris & Paltrow, 2003). An ethical paper outlines two criteria that, 
when met, does not violate nonmaleficence or beneficence obligations to the fetus.  The 
beneficence-based obligation to the fetus has reached its limits if there is (1) a certainty or very 
high probability of a correct diagnosis, and (2) either certainty or a very high probability of death 
or severe irreversible deficit of cognitive developmental capacity as a result of the diagnosis 
(Chervenak & McCullough, 2009).  Even when an ethical obligation exists, they do not have 
equal weight to legal obligations (Harris & Paltrow, 2003). Numerous court decisions have 
concluded that neither fetal rights nor state interests on behalf of the fetus supersede a woman’s 
autonomy or rights as the ultimate medical decision maker (Harris & Paltrow, 2003). 
The most important of the ethical principles to uphold in this situation is the mother’s 
autonomy (Harris & Paltrow, 2003).  To respect a patient’s self-determination, a physician must 
provide patients with evidenced-based clinical information that allows the mother to make a 
competent decision.  The health care team must provide nondirective counseling as to not 
suggest or imply a recommendation (Chervenak & McCullough, 2009).  A mother’s decision on 
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her course of treatment or lack of treatment should be her own. Attempting to bias a woman’s 
treatment decision violates her autonomy.   Respect for the mother’s autonomy includes 
respecting her treatment decisions, even if they are in conflict with the health care provider’s 
moral beliefs.  
Conclusion 
It is my opinion there will be two areas of nursing practice that will see the impact of 
cancer during pregnancy – oncology nursing and obstetric nursing.  Oncology nurses will see a 
rise in pregnant patients and obstetric nurses will see a rise in oncology patients because these 
patients are one in the same.  A rise in cancer during pregnancy will require that nurses become 
cross-disciplinary.  With cross-disciplinary training, the nurse will be better equipped to handle 
this delicate situation. A nurse who is educated in both obstetrics and oncology will be able to 
provide answers to questions that are unique to a patient who is battling cancer while being 
pregnant. 
 Until new medications are established or the safety of current treatments on a fetus is 
solidly established, the nursing community must be aware of the treatment decisions that must be 
made.  With any of the treatment options, the health care team could be faced with an ethical 
dilemma.  Does the health care team uphold the principles of beneficence to the mother by 
treating the cancer, while simultaneously violating nonmaleficence toward the fetus? Or, does 
the health care team show beneficence to the fetus by not exposing it to harmful anti-cancer 
treatments and risk placing the mother in harm’s way?   The nurse will have his or her own 
opinions on what course of treatment a mother should choose; however, it is important to 
remember the nurse’s role is to serve a patient advocate.  Deciding on a course of treatment will 
not come with ease; however, it is one that will have to be made by the mother.    
The Journal of Undergraduate Nursing Writing. Volume 5, Issue 1. August 2011. 28
Dudley, K. To Treat or Not To Treat?: Cancer During Pregnancy. 2011 
References 
Chervenak, F. A., & McCullough, L. B. (2009). An ethically justified practical approach to 
offering, recommending, performing, and referring for induced abortion and feticide. 
American Journal of Obstetrics and Gynecology, 201(6), 560.e1-560.e6. doi: 
10.1016/j.ajog.2009.05.057 
Harris, L. (2000). Rethinking maternal-fetal conflict: gender and equality in perinatal ethics. 
Obstetrics & Gynecology, 96(5 part 1), 786-791. 
Harris, L., & Paltrow, L. (2003). The status of pregnant women and fetuses in US criminal law. 
JAMA: Journal of the American Medical Association, 289(13), 1697-1699. 
Moran, B. J., Yano, H., Al Zahir, N., & Farquharson, M. (2007). Conflicting priorities in surgical 
intervention for cancer in pregnancy. The Lancet Oncology, 8(6), 536-544. doi: 
10.1016/S1470-2045(07)70171-7 
Mathews, T. J., & Hamilton, B. E. (2009, August). Delayed Childbearing: More Women Are 
Having Their (United States Department of Health and Human Services, Center for 
Disease Control). Retrieved from http://www.cdc.gov/nchs/data/databriefs/db21.pdf 
Nettleton, J., Long, J., Kuban, D., Wu, R., Shaeffer, J., & El-Mahdi, A. (1996). Breast cancer 
during pregnancy: quantifying the risk of treatment delay. Obstetrics and Gynecology, 
87(3), 414-418. doi: 10.1016/0029-7844(95)00470-X 
Otake, M., Schull, W.J. (1998).  Radiation-related brain damage and growth retardation among 
the prenatally exposed atomic bomb survivors. International Journal of Radiation 
Biology. 74(2):159-71. 
Pavlidis, N. A. (2002). Coexistence of pregnancy and malignancy. Oncologist, 7, 279-287. doi: 
10.1634/theoncologist.7-6-573 
The Journal of Undergraduate Nursing Writing. Volume 5, Issue 1. August 2011. 29
Dudley, K. To Treat or Not To Treat?: Cancer During Pregnancy. 2011 
Pereg, D., Koren, G., & Lishner, M. (2008). Cancer in pregnancy: Gaps, challenges and 
solutions. Cancer Treatment Reviews, 34(4), 302-312. doi:10.1016/j.ctrv.2008.01.002  
Van Calsteren, K., Heyns, L., De Smet, F., Van Eycken, L., Gziri, M., Van Gemert, W., et al. 
(2010). Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical 
and the neonatal outcomes. Journal of Clinical Oncology, 28(4), 683-689. doi: 
10.1200/JCO.2009.23.2801 
Visco, A., Meyer, L., Xi, S., & Brown, C. (2009). One disease, two lives: exploring the treatment 
of breast cancer during pregnancy. Clinical Journal of Oncology Nursing, 13(4), 426-
432. 
Weisz, B., Meirow, D., Schiff, E., & Lishner, M. (2004). Impact and treatment of cancer during 
pregnancy. Expert Review of Anticancer Therapy, 4(5), 889-902. doi: 
10.1586/14737140.4.5.889 
When cancer strikes during pregnancy, improving the odds demands teamwork. (2010, March 
31). University of California Davis Health System. Retrieved from 
http://www.ucdmc.ucdavis.edu/welcome/features/20100331_Synthesis_cancer_pregnanc
y/index.html 
The Journal of Undergraduate Nursing Writing. Volume 5, Issue 1. August 2011. 30
